Veldink JH - Search Results

1

A randomized sequential trial of creatine in amyotrophic lateral sclerosis.

Groeneveld GJ, Veldink JH, van der Tweel I, Kalmijn S, Beijer C, de Visser M, Wokke JH, Franssen H, van den Berg LH. Groeneveld GJ, et al. Among authors: veldink jh. Ann Neurol. 2003 Apr;53(4):437-45. doi: 10.1002/ana.10554. Ann Neurol. 2003. PMID: 12666111 Clinical Trial.

2

Homozygous deletion of the survival motor neuron 2 gene is a prognostic factor in sporadic ALS.

Veldink JH, van den Berg LH, Cobben JM, Stulp RP, De Jong JM, Vogels OJ, Baas F, Wokke JH, Scheffer H. Veldink JH, et al. Neurology. 2001 Mar 27;56(6):749-52. doi: 10.1212/wnl.56.6.749. Neurology. 2001. PMID: 11274309

3

Inter- and intraindividual variability of riluzole serum concentrations in patients with ALS.

Groeneveld GJ, van Kan HJ, Toraño JS, Veldink JH, Guchelaar HJ, Wokke JH, van den Berg LH. Groeneveld GJ, et al. Among authors: veldink jh. J Neurol Sci. 2001 Oct 15;191(1-2):121-5. doi: 10.1016/s0022-510x(01)00613-x. J Neurol Sci. 2001. PMID: 11677002 Clinical Trial.

4

Euthanasia and physician-assisted suicide among patients with amyotrophic lateral sclerosis in the Netherlands.

Veldink JH, Wokke JH, van der Wal G, Vianney de Jong JM, van den Berg LH. Veldink JH, et al. N Engl J Med. 2002 May 23;346(21):1638-44. doi: 10.1056/NEJMsa012739. N Engl J Med. 2002. PMID: 12023997 Free article.

5

Physician-assisted death: dying with dignity?

Reagan P, Hurst R, Cook L, Zylicz Z, Otlowski M, Veldink JH, van den Berg LH, Wokke JH. Reagan P, et al. Among authors: veldink jh. Lancet Neurol. 2003 Oct;2(10):637-43. doi: 10.1016/s1474-4422(03)00536-2. Lancet Neurol. 2003. PMID: 14505588 No abstract available.

6

Sexual differences in onset of disease and response to exercise in a transgenic model of ALS.

Veldink JH, Bär PR, Joosten EA, Otten M, Wokke JH, van den Berg LH. Veldink JH, et al. Neuromuscul Disord. 2003 Nov;13(9):737-43. doi: 10.1016/s0960-8966(03)00104-4. Neuromuscul Disord. 2003. PMID: 14561497

7

Riluzole serum concentrations in patients with ALS: associations with side effects and symptoms.

Groeneveld GJ, Van Kan HJ, Kalmijn S, Veldink JH, Guchelaar HJ, Wokke JH, Van den Berg LH. Groeneveld GJ, et al. Among authors: veldink jh. Neurology. 2003 Oct 28;61(8):1141-3. doi: 10.1212/01.wnl.0000090459.76784.49. Neurology. 2003. PMID: 14581684 Clinical Trial.

8

Zinc amplifies mSOD1-mediated toxicity in a transgenic mouse model of amyotrophic lateral sclerosis.

Groeneveld GJ, de Leeuw van Weenen J, van Muiswinkel FL, Veldman H, Veldink JH, Wokke JH, Bär PR, van den Berg LH. Groeneveld GJ, et al. Among authors: veldink jh. Neurosci Lett. 2003 Dec 11;352(3):175-8. doi: 10.1016/j.neulet.2003.08.062. Neurosci Lett. 2003. PMID: 14625013

9

The future of motor neuron disease: the challenge is in the genes.

Veldink JH, Van den Berg LH, Wokke JH. Veldink JH, et al. J Neurol. 2004 Apr;251(4):491-500. doi: 10.1007/s00415-004-0322-6. J Neurol. 2004. PMID: 15083302 Review.

10

[From gene to disease: amyotrophic lateral sclerosis].

van Vught PW, Veldink JH, Baas F, van Muiswinkel FL, van den Berg LH. van Vught PW, et al. Among authors: veldink jh. Ned Tijdschr Geneeskd. 2004 Oct 23;148(43):2125-7. Ned Tijdschr Geneeskd. 2004. PMID: 15553356 Review. Dutch.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

373 results

Search Page

Filters